Kyntra Bio/$KYNB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Kyntra Bio
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
- Ticker
- $KYNB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 34
- Headquarters
- San Francisco, United States
- Website
- www.kyntrabio.com
Kyntra Bio Metrics
BasicAdvanced
$15M
0.08
$45.27
1.06
-
Price and volume
Market cap
$15M
Beta
1.06
52-week high
$10.47
52-week low
$3.50
Average daily volume
26K
Financial strength
Current ratio
2.687
Quick ratio
2.543
Interest coverage (TTM)
-5.41%
Profitability
EBITDA (TTM)
-50.035
Gross margin (TTM)
-489.06%
Net profit margin (TTM)
3,968.63%
Operating margin (TTM)
-1,088.56%
Effective tax rate (TTM)
0.00%
Revenue per employee (TTM)
$140,000
Management effectiveness
Return on assets (TTM)
-22.50%
Return on equity (TTM)
32.68%
Valuation
Price to earnings (TTM)
0.081
Price to revenue (TTM)
3.226
Price to book
-0.49
Price to tangible book (TTM)
-0.49
Price to free cash flow (TTM)
-0.391
Free cash flow yield (TTM)
-255.57%
Free cash flow per share (TTM)
-9.405
Growth
Revenue change (TTM)
-37.16%
Earnings per share change (TTM)
-8,938.52%
3-year revenue growth (CAGR)
-67.18%
10-year revenue growth (CAGR)
-29.92%
3-year earnings per share growth (CAGR)
-18.86%
10-year earnings per share growth (CAGR)
1.13%
Kyntra Bio Financial Performance
Revenues and expenses
Kyntra Bio Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.